Stockreport

Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies [TheStreet.com]

Eli Lilly and Company  (LLY) 
Last eli lilly and company earnings: 4/23 06:25 am Check Earnings Report
US:NYSE Investor Relations: investor.lilly.com
PDF INDIANAPOLIS and BOSTON, Mass., April 20, 2026 Kelonia's lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 [Read more]